The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors
Open accessAbstract
The dense collagen network in tumors significantly reduces the penetration and efficacy of nanotherapeutics. We tested whether losartan—a clinically approved angiotensin II receptor antagonist with noted antifibrotic activity—can enhance the penetration and efficacy of nanomedicine. We found that losartan inhibited collagen I production by carcinoma-associated fibroblasts isolated from breast cancer biopsies. Additionally, it led to a dose-dependent reduction in stromal collagen in desmoplastic models of human breast, pancreatic, and skin tumors in mice. Furthermore, losartan improved the distribution and therapeutic efficacy of intratumorally injected oncolytic herpes simplex viruses. Finally, it also enhanced the efficacy of i.v. injected pegylated liposomal doxorubicin (Doxil). Thus, losartan has the potential to enhance the efficacy of nanotherapeutics in patients with desmoplastic tumors.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Increased mechanical stress can collapse blood vessels, leading to hypoxia, thereby promoting more aggressive cancer phenotypes, and reducing drug delivery89,100–105.”
From A framework for advancing our understanding of cancer-associated fibroblasts (2020) · cites this paper as [100]
Citations
Cites
Nanocarriers as an emerging platform for cancer therapy
Peer, D., Karp, J. M., Hong, S., Farokhzad, O. C., Margalit, R., & Langer, R. (2007) · Nature Nanotechnology · doi:10.1038/nnano.2007.387 · Cited by 8,710
Recent advances with liposomes as pharmaceutical carriers
Torchilin, V. P. (2005) · Nature Reviews Drug Discovery · doi:10.1038/nrd1632 · Cited by 5,282
Nanoparticle therapeutics: an emerging treatment modality for cancer
Davis, M. E., Chen, Z., & Shin, D. M. (2008) · Nature Reviews Drug Discovery · doi:10.1038/nrd2614 · Cited by 4,233
Delivering nanomedicine to solid tumors
Jain, R. K., & Stylianopoulos, T. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.139 · Cited by 3,265
Self-citationOlive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Collagens—structure, function, and biosynthesis
Gelse, K. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2003.08.002 · Cited by 2,777
Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome
Habashi, J. P., Judge, D. P., Holm, T. M., Cohn, R. D., Loeys, B. L., Cooper, T. K., Myers, L., Klein, E. C., Liu, G., Calvi, C., et al. (2006) · Science · doi:10.1126/science.1124287 · Cited by 1,794
Molecular mechanisms of drug resistance
Longley, D., & Johnston, P. (2005) · The Journal of Pathology · doi:10.1002/path.1706 · Cited by 1,726
Role of extracellular matrix assembly in interstitial transport in solid tumors.
Netti, P. A., Berk, D. A., Swartz, M. A., Grodzinsky, A. J., & Jain, R. K. (2000) · PubMed · Cited by 1,165
Self-citationDynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation
Brown, E. B., McKee, T. D., DiTomaso, E., Pluen, A., Seed, B., Boucher, Y., & Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm879 · Cited by 844
Self-citation
Cited by
Sorted by citations
Items 301–400 of 734
Song, Y., Kim, J.-S., Choi, E. K., Kim, J., Kim, K. M., & Seo, H. R. (2017) · Oncotarget · doi:10.18632/oncotarget.15521 · Cited by 47
Bridging the Knowledge of Different Worlds to Understand the Big Picture of Cancer Nanomedicines
Balasubramanian, V., Liu, Z., Hirvonen, J. J., & Santos, H. A. (2017) · Advanced Healthcare Materials · doi:10.1002/adhm.201700432 · Cited by 48
Enzyme-responsive nano-drug delivery system for combined antitumor therapy
Guo, F., Jiao, Y., Du, Y., Luo, S., Hong, W., Fu, Q., Li, A., Wang, G., & Yang, G. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.08.123 · Cited by 44
Augmentation of the EPR effect by mild hyperthermia to improve nanoparticle delivery to the tumor
Aloss, K., & Hamar, P. (2024) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2024.189109 · Cited by 49
G-protein coupled receptors of the renin-angiotensin system: new targets against breast cancer?
Rodrigues-Ferreira, S., & Nahmias, C. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00024 · Cited by 46
Piehler, S., Wucherpfennig, L., Tansi, F. L., Berndt, A., Quaas, R., Teichgraeber, U. K., & Hilger, I. (2020) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2020.102183 · Cited by 47
Recent advances in tumor microenvironment associated therapeutic strategies and evaluation models
Haider, T., Sandha, K. K., Soni, V., & Gupta, P. N. (2020) · Materials Science and Engineering C · doi:10.1016/j.msec.2020.111229 · Cited by 44
Engineering Intelligent Nanosystems for Enhanced Medical Imaging
van Moolenbroek, G. T., Patiño, T., Llop, J., & Sánchez, S. (2020) · Advanced Intelligent Systems · doi:10.1002/aisy.202000087 · Cited by 46
Characterization of the mechanical properties of microgels acting as cellular microenvironments
Kumachev, A., Tumarkin, E., Walker, G. C., & Kumacheva, E. (2013) · Soft Matter · doi:10.1039/c3sm27400d · Cited by 45
Advanced cancer therapy by integrative antitumor actions via systemic administration of miR-499
Ando, H., Asai, T., Koide, H., Okamoto, A., Maeda, N., Tomita, K., Dewa, T., Minamino, T., & Oku, N. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.02.019 · Cited by 43
Fibrin degradation by rtPA enhances the delivery of nanotherapeutics to A549 tumors in nude mice
Zhang, B., Jiang, T., She, X., Shen, S., Wang, S., Deng, J., Shi, W., Mei, H., Hu, Y., Pang, Z., et al. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.04.015 · Cited by 44
Nano-sized drug carriers: Extravasation, intratumoral distribution, and their modeling
Nichols, J. W., Sakurai, Y., Harashima, H., & Bae, Y. H. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.08.003 · Cited by 44
Obstacles to T cell migration in the tumor microenvironment
Nicolás‐Boluda, A., & Donnadieu, E. (2018) · Comparative Immunology Microbiology and Infectious Diseases · doi:10.1016/j.cimid.2018.12.006 · Cited by 45
Zhu, Y., Meng, T., Tan, Y., Yang, X., Liu, Y., Liu, X., Yu, F., Wen, L., Dai, S., Yuan, H., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00842 · Cited by 42
Guo, D., Shi, C., Wang, X., Wang, L., Zhang, S., & Luo, J. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.06.041 · Cited by 42
Zhu, Y., Yu, F., Tan, Y., Hong, Y. K., Meng, T., Liu, Y., Dai, S., Qiu, G., Yuan, H., & Hu, F. (2019) · Theranostics · doi:10.7150/thno.36334 · Cited by 42
Zhang, B., Shi, W., Jiang, T., Wang, L., Mei, H., Lu, H., Hu, Y., & Pang, Z. (2016) · Oncotarget · doi:10.18632/oncotarget.11546 · Cited by 41
Panagi, M., Mpekris, F., Voutouri, C., Hadjigeorgiou, A. G., Symeonidou, C., Porfyriou, E., Michael, C., Stylianou, A., Martin, J. D., Cabral, H., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0246 · Cited by 47
Nanomechanical properties of solid tumors as treatment monitoring biomarkers
Stylianou, A., Mpekris, F., Voutouri, C., Papoui, A., Constantinidou, A., Kitiris, E., Kailides, M., & Stylianopoulos, T. (2022) · Acta Biomaterialia · doi:10.1016/j.actbio.2022.10.021 · Cited by 42
Hu, H., Zhang, W., Lei, L., Tong, F., Zhang, H., Zhang, Y., Yang, W., Tang, Y., Lin, R., Xia, X., et al. (2023) · Chinese Chemical Letters · doi:10.1016/j.cclet.2023.108765 · Cited by 41
Liang, H., Ren, X., Qian, J., Zhang, X., Meng, L., Wang, X., Li, L., Fang, X., & Sha, X. (2016) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.6b00668 · Cited by 40
De Lellis, L., Veschi, S., Tinari, N., Mokini, Z., Carradori, S., Brocco, D., Florio, R., Grassadonia, A., & Cama, A. (2021) · Cancers · doi:10.3390/cancers13163946 · Cited by 40
Promise and Challenges of T Cell Immunotherapy for Osteosarcoma
Park, J. A., & Cheung, N. V. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241512520 · Cited by 45
Knipper, K., Lyu, S. I., Quaas, A., Bruns, C. J., & Schmidt, T. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms241713482 · Cited by 41
Unfolding the Role of Stress Response Signaling in Endocrine Resistant Breast Cancers
Clarke, R. C., & Cook, K. L. (2015) · Frontiers in Oncology · doi:10.3389/fonc.2015.00140 · Cited by 40
Molecular MR imaging of fibrosis in a mouse model of pancreatic cancer
Polášek, M., Yang, Y., Schühle, D. T., Yaseen, M. A., Kim, Y. R., Sung, Y. S., Guimarães, A. R., & Caravan, P. D. (2017) · Scientific Reports · doi:10.1038/s41598-017-08838-6 · Cited by 39
Zhang, Y., Liu, Y., Gao, X., Li, X., Niu, X., Yuan, Z., & Wang, W. (2019) · Acta Biomaterialia · doi:10.1016/j.actbio.2019.04.022 · Cited by 39
Vallejo-Ardila, D. L., Walsh, K. A., Fifis, T., Paolini, R. A., Kastrappis, G., Christophi, C., & Perini, M. V. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000487 · Cited by 39
Tumor vasculature-targeting nanomedicines
Zhang, Y., & He, J. (2021) · Acta Biomaterialia · doi:10.1016/j.actbio.2021.07.015 · Cited by 38
Recent advances in targeted therapy for pancreatic adenocarcinoma
Fang, Y., Yang, W., Niu, Y., & Sun, Y. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i4.571 · Cited by 40
Tumour tissue transport after intraperitoneal anticancer drug delivery
Carlier, C., Mathys, A., Jaeghere, E. A. D., Steuperaert, M., Wever, O. D., & Ceelen, W. P. (2017) · International Journal of Hyperthermia · doi:10.1080/02656736.2017.1312563 · Cited by 39
Novel agents for pancreatic ductal adenocarcinoma: emerging therapeutics and future directions
Zhang, Y., Yang, C., Cheng, H., Fan, Z., Huang, Q., Yu, L., Fan, K., Luo, G., Jin, K., Wang, Z., et al. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-017-0551-7 · Cited by 41
Shen, H., Gao, Q., Qi, Y., Yang, S., Wu, Y., Huang, Q., Wang, X., & Sun, Z. (2018) · International Journal of Nanomedicine · doi:10.2147/ijn.s178585 · Cited by 39
Investigating the role of peptides in effective therapies against cancer
Naeimi, R., Bahmani, A., & Afshar, S. (2022) · Cancer Cell International · doi:10.1186/s12935-022-02553-7 · Cited by 38
Angiotensin Receptor Blockers Are Not Just for Hypertension Anymore
Saavedra, J. M. (2021) · Physiology · doi:10.1152/physiol.00036.2020 · Cited by 37
Tanaka, H. Y., Nakazawa, T., Enomoto, A., Masamune, A., & Kano, M. R. (2023) · Cancers · doi:10.3390/cancers15030724 · Cited by 42
Tajaldini, M., Poorkhani, A., Amiriani, T., Amiriani, A., Javid, H., Aref, P., Ahmadi, F., Sadani, S., & Khori, V. (2023) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2023.175991 · Cited by 38
Extracellular matrix macromolecules: potential tools and targets in cancer gene therapy
Sainio, A., & Järveläinen, H. (2014) · Molecular and Cellular Therapies · doi:10.1186/2052-8426-2-14 · Cited by 38
Chauhan, V. P., Popović, Z., Chen, O., Cui, J., Fukumura, D., Bawendi, M. G., & Jain, R. K. (2011) · Angewandte Chemie · doi:10.1002/ange.201104449 · Cited by 37
Self-citationJiang, L., Zhang, M., Bai, Y., Cui, F., Zhang, C., Wang, Z., Si, S., Yang, L., Wang, Y., Zhang, Y., et al. (2021) · Carbohydrate Polymers · doi:10.1016/j.carbpol.2021.118611 · Cited by 37
Willumsen, N., Jensen, C., Green, G. A., Nissen, N. I., Neely, J., Nelson, D. M., Pedersen, R. S., Frederiksen, P., Chen, I. M., Boisen, M. K., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04226-0 · Cited by 37
Nanomaterial-Based Drug Delivery Systems: A New Weapon for Cancer Immunotherapy
Jiang, Z., Zhang, W., Zhang, J., Liu, T., Xing, J., Zhang, H., & Tang, D. (2022) · International Journal of Nanomedicine · doi:10.2147/ijn.s376216 · Cited by 36
Lee, E. M., Kim, A.-Y., Lee, E. H., Park, J., Lee, M., Hwang, M., Kim, C.-Y., Kim, S., & Jeong, K. (2014) · Cell Transplantation · doi:10.3727/096368914x678599 · Cited by 36
Boosting antitumor efficacy of nanoparticles by modulating tumor mechanical microenvironment
Zhang, X., Zhang, X., Yong, T., Gan, L., & Yang, X. (2024) · EBioMedicine · doi:10.1016/j.ebiom.2024.105200 · Cited by 36
Oncolytic Herpes Simplex Viral Therapy: A Stride toward Selective Targeting of Cancer Cells
Sanchala, D., Bhatt, L. K., & Prabhavalkar, K. S. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00270 · Cited by 36
Modulating the rigidity of nanoparticles for tumor penetration
Deng, H., Song, K., Zhang, J., Deng, L., Dong, A., & Qin, Z. (2018) · Chemical Communications · doi:10.1039/c8cc00398j · Cited by 36
Measles Vaccine Strains for Virotherapy of Non–Small-Cell Lung Carcinoma
Patel, M. R., Jacobson, B. A., Belgum, H., Raza, A., Sadiq, A. A., Drees, J. J., Wang, H., Jay-Dixon, J., Etchison, R. G., Federspiel, M. J., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000214 · Cited by 36
Cancer-associated fibroblasts: Mediators of head and neck tumor microenvironment remodeling
Raudenská, M., Balvan, J., Hánělová, K., Bugajová, M., & Masařík, M. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188940 · Cited by 37
Zhang, X., Al-Danakh, A., Zhu, X., Feng, D., Yang, L., Wu, H., Li, Y., Wang, S., Chen, Q., & Yang, D. (2024) · Bioengineering & Translational Medicine · doi:10.1002/btm2.10698 · Cited by 36
The role of stromal fibroblasts in lung carcinogenesis: A target for chemoprevention?
Mahale, J., Smagurauskaite, G., Brown, K., Thomas, A., & Howells, L. M. (2015) · International Journal of Cancer · doi:10.1002/ijc.29447 · Cited by 35
The Other Angiotensin II Receptor: AT2R as a Therapeutic Target
Juillerat‐Jeanneret, L. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b01780 · Cited by 35
Gouardères, S., Mingotaud, A., Vicendo, P., & Gibot, L. (2020) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2020.1814735 · Cited by 35
Lan, H., We, Z., Jin, K., Liu, Y., & Wang, Z. (2020) · Drug Delivery · doi:10.1080/10717544.2020.1809559 · Cited by 35
Immunovirotherapy: The role of antibody based therapeutics combination with oncolytic viruses
Jafari, M., Kadkhodazadeh, M., Shapourabadi, M. B., Goradel, N. H., Shokrgozar, M. A., Arashkia, A., Abdoli, S., & Sharifzadeh, Z. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1012806 · Cited by 37
da Silva, W., Costa, P. A. C., Scalzo, S., Ferreira, H. A. S., Prazeres, P. H. D. M., Campos, C., Alves, M. T. R., da Silva, N. J. A., Santos, A. L. D. C., Guimarães, L. C., et al. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s452896 · Cited by 34
The BRAFV600E inhibitor, PLX4032, increases type I collagen synthesis in melanoma cells
Jenkins, M. H., Croteau, W., Mullins, D. W., & Brinckerhoff, C. (2015) · Matrix Biology · doi:10.1016/j.matbio.2015.05.007 · Cited by 37
Durymanov, M., Kroll, C., Permyakova, A., O'Neill, E., Sulaiman, R., Person, M., & Reineke, J. (2019) · Translational Oncology · doi:10.1016/j.tranon.2018.10.003 · Cited by 34
Immune‐mediated ECM depletion improves tumour perfusion and payload delivery
Yeow, Y. L., Kotamraju, V. R., Wang, X., Chopra, M., Azme, N., Wu, J., Schoep, T. D., Delaney, D. S., Feindel, K. W., Li, J., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910923 · Cited by 35
Remodeling tumor microenvironment with nanomedicines
Martin, J. D., Miyazaki, T., & Cabral, H. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1730 · Cited by 35
Fobian, S., Cheng, Z., & ten Hagen, T. L. M. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics14010026 · Cited by 35
Zhao, H., Li, R., Chen, Y., Yang, X. Y., & Shang, Z. (2023) · Oncogene · doi:10.1038/s41388-023-02642-5 · Cited by 37
Clinical Strategies Targeting the Tumor Microenvironment of Pancreatic Ductal Adenocarcinoma
Skorupan, N., Domínguez, M. P., Ricci, S. L., & Alewine, C. (2022) · Cancers · doi:10.3390/cancers14174209 · Cited by 35
Advances in nuclei targeted delivery of nanoparticles for the management of cancer
Goyal, P., & Malviya, R. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188881 · Cited by 33
Intelligent Size-Changeable Nanoparticles for Enhanced Tumor Accumulation and Deep Penetration
Yu, W., Hu, C., & Gao, H. (2020) · ACS Applied Bio Materials · doi:10.1021/acsabm.0c00917 · Cited by 33
Stromal disruption facilitating invasion of a ‘nano-arsenal’ into the solid tumor
Fu, Y., Saraswat, A. L., Monpara, J. D., & Patel, K. R. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.11.015 · Cited by 33
Modulating Tumor Extracellular Matrix by Simultaneous Inhibition of Two Cancer Cell Receptors
Chen, W., Yang, Y., Cheng, L., Mao, H. Z., Liu, B., & Jiang, X. (2021) · Advanced Materials · doi:10.1002/adma.202109376 · Cited by 31
Cancer‐associated fibroblasts: Is it a key to an intricate lock of tumorigenesis?
Aden, D., Zaheer, S., Ahluwalia, H., & Ranga, S. (2023) · Cell Biology International · doi:10.1002/cbin.12004 · Cited by 33
Angiotensin receptor blocker attacks armored and cold tumors and boosts immune checkpoint blockade
Mei, J., Chu, J., Yang, K. G., Luo, Z., Yang, J., Xu, J., Li, Q., Zhang, Y., Zhang, Q., Wan, M., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009327 · Cited by 33
Nanocarrier strategies for deep tumour penetration
Zhang, J., Wu, G., & Bobrin, V. A. (2025) · RSC Applied Polymers · doi:10.1039/d5lp00154d · Cited by 34
Zhang, L., Wang, Y., Xia, T., Yu, Q., Zhang, Q., Yang, Y., Cun, X., Lu, L., Gao, H., Zhang, Z., et al. (2016) · Drug Delivery · doi:10.3109/10717544.2015.1132798 · Cited by 32
Angiotensin blockade therapy and survival in pancreatic cancer: a population study
Keith, S. W., Maio, V., Arafat, H. A., Alcusky, M. J., Karagiannis, T., Rabinowitz, C., Lavu, H., & Louis, D. Z. (2022) · BMC Cancer · doi:10.1186/s12885-022-09200-4 · Cited by 33
Targeting GRP78 and Antiestrogen Resistance in Breast Cancer
Cook, K. L., Clarke, P. A. G., & Clarke, R. C. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.77 · Cited by 32
Overcoming the Fibrotic Fortress in Pancreatic Ductal Adenocarcinoma: Challenges and Opportunities
Min, K. K. M., Ffrench, C. B., Jessup, C. F., Shepherdson, M., Barreto, S. G., & Bonder, C. S. (2023) · Cancers · doi:10.3390/cancers15082354 · Cited by 35
Wu, Z., Tang, Y., Liu, Y., Chen, Z., Feng, Y., Hu, H., Liu, H., Chen, G., Lu, Y., Hu, Y., et al. (2024) · Journal of Advanced Research · doi:10.1016/j.jare.2024.04.017 · Cited by 31
Perry, S. W., Schueckler, J. M., Burke, K. A., Arcuri, G. L., & Brown, E. B. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-411 · Cited by 31
Endothelial Thermotolerance Impairs Nanoparticle Transport in Tumors
Bagley, A. F., Scherz‐Shouval, R., Galie, P. A., Zhang, A. Q., Wyckoff, J. B., Whitesell, L. J., Chen, C. S., Lindquist, S. L., & Bhatia, S. N. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-0325 · Cited by 31
Tang, Y., Liu, Y., Wang, S., Tian, Y., Li, Y., Teng, Z., & Lu, G. (2019) · Drug Delivery and Translational Research · doi:10.1007/s13346-018-00610-1 · Cited by 31
Nanomedicine Strategies for Targeting Tumor Stroma
Su, M., Nethi, S. K., Dhanyamraju, P. K., & Prabha, S. (2023) · Cancers · doi:10.3390/cancers15164145 · Cited by 32
Lu, Y., Lian, S., Ye, Y., Yu, T., Liang, H., Cheng, Y., Xie, J., Zhu, Y., Xie, X., Yu, S., et al. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.10.020 · Cited by 31
Yu, J., Kong, X., & Feng, Y. (2025) · Cancer Drug Resistance · doi:10.20517/cdr.2025.14 · Cited by 32
How do nanoparticle properties shape pharmacokinetics and pharmacodynamics? A mechanistic review
Peralta-Cuevas, E., Degollado-Hernández, N. Y., Martínez-Ortíz, I. C., Gutierrez-Onofre, A. J., Garcia-Atutxa, I., & Villanueva-Flores, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1704814 · Cited by 34
Yata, T., Lee, E. L. Q., Suwan, K., Syed, N., Asavarut, P., & Hajitou, A. (2015) · Molecular Cancer · doi:10.1186/s12943-015-0383-4 · Cited by 31
Angeli, S., Neophytou, C., Kalli, M., Stylianopoulos, T., & Mpekris, F. (2025) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2025.1564626 · Cited by 34
Chen, J., Li, S., Liu, X., Liu, S., Xiao, C., Zhang, Z., Li, S., Li, Z., & Yang, X. (2021) · Nanoscale · doi:10.1039/d1nr01552d · Cited by 28
Microvascular significance of TGF-β axis activation in COVID-19
Arguinchona, L., Zagona‐Prizio, C., Joyce, M. E., Chan, E. D., & Maloney, J. P. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1054690 · Cited by 30
Angiotensin II inhibitor facilitates epidermal wound regeneration in diabetic mice
eKamber, M., Papalazarou, V., Rouni, G., Papageorgopoulou, E., Papalois, A., & Kostourou, V. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00170 · Cited by 28
Burke, R. M., Madden, K. S., Perry, S. W., Zettel, M. L., & Brown, E. B. (2013) · Journal of Biomedical Optics · doi:10.1117/1.jbo.18.8.086003 · Cited by 28
Aghlara-Fotovat, S., Nash, A., Kim, B., Krencik, R., & Omid Veiseh, A. (2021) · Drug Delivery and Translational Research · doi:10.1007/s13346-021-01018-0 · Cited by 29
The Role of Extracellular Matrix Remodeling in Skin Tumor Progression and Therapeutic Resistance
Fromme, J. E., & Zigrino, P. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.864302 · Cited by 27
Olaoba, O. T., Yang, M. J., Adelusi, T. I., Maidens, T., Kimchi, E. T., Staveley-O’Carroll, K. F., & Li, G. (2024) · Cancers · doi:10.3390/cancers16081470 · Cited by 28
Image-Guided Radiotherapy Targets Macromolecules through Altering the Tumor Microenvironment
Appelbe, O. K., Zhang, Q., Pelizzari, C. A., Weichselbaum, R. R., & Kron, S. J. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00465 · Cited by 27
Cho, M. A., Jeong, S. Y., Sohn, I., Kim, M.-S., Kang, J. H., Paik, E. S., Lee, Y.-Y., & Choi, C. H. (2020) · Cancer Research and Treatment · doi:10.4143/crt.2019.509 · Cited by 27
Drug Repurposing Opportunities in Pancreatic Ductal Adenocarcinoma
Rebelo, R., Polónia, B. R. G., Santos, L. L., Vasconcelos, M. H., & Xavier, C. P. R. (2021) · Pharmaceuticals · doi:10.3390/ph14030280 · Cited by 30
Bian, S., Dong, H., Zhao, L., Li, Z., Chen, J., Zhu, X., Qiu, N., Jia, X., Song, W., Li, Z., et al. (2022) · Advanced Science · doi:10.1002/advs.202201931 · Cited by 28
Physics of the tumor vasculature: Theory and experiment
Rieger, H., Fredrich, T., & Welter, M. (2016) · The European Physical Journal Plus · doi:10.1140/epjp/i2016-16031-9 · Cited by 26
Li, W., Li, S., Chen, I. X., Liu, Y., Ramjiawan, R. R., Leung, S. C. H., Gerweck, L. E., Fukumura, D., Loeffler, J. S., Jain, R. K., et al. (2021) · Radiation Oncology · doi:10.1186/s13014-021-01775-9 · Cited by 27
Self-citationPharmacokinetics and Tissue Transport of Intraperitoneal Chemotherapy
Lagast, N., Carlier, C., & Ceelen, W. P. (2018) · Surgical Oncology Clinics of North America · doi:10.1016/j.soc.2018.02.003 · Cited by 27
Restriction of drug transport by the tumor environment
Nandigama, R., Upcin, B., Aktas, B. H., Ergün, S., & Henke, E. (2018) · Histochemistry and Cell Biology · doi:10.1007/s00418-018-1744-z · Cited by 28
Balkrishnan, R., Desai, R. P., Narayan, A. P., Camacho, F., Flausino, L. E., & Chammas, R. J. (2021) · Cancer Medicine · doi:10.1002/cam4.4088 · Cited by 26
Arthur, P., Patel, N., Surapaneni, S. K., Mondal, A., Gebeyehu, A., Bagde, A., Kutlehria, S., Nottingham, E., & Singh, M. S. (2020) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2020.115112 · Cited by 26
Metadata
- Authors
- Diop-Frimpong, B., Chauhan, V. P., Krane, S., Boucher, Y., & Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Proceedings of the National Academy of Sciences
- Publisher
- National Academy of Sciences
- Published
- 2011-01-31
- Volume
- 108
- Issue
- 7
- Pages
- 2909-2914
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- PMC
- PMC3041115
- OpenAlex
- W2098054841
- Cited by
- 733
- References
- 54
- Citations by year
- 2026: 38 · 2025: 51 · 2024: 63 · 2023: 55 · 2022: 65 · 2021: 77 · 2020: 84 · 2019: 47 · 2018: 43 · 2017: 51 · 2016: 40 · 2015: 40 · 2014: 20 · 2013: 28 · 2012: 24
- FWCI
- 10.23
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Proceedings of the National Academy of Sciences (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- DSpace@MIT (Massachusetts Institute of Technology) (submittedVersion, cc-by-nc)
- Funders
- U.S. Department of Defense (W81XWH1010016, W81XWH)
- AstraZeneca
- FibroGen
- Astellas Pharma
- National Cancer Institute (W81XWH-10-1-0016, R01 CA 85140, R01CA98706, R01CA085140, P01CA080124, R01CA098706, P01-CA-80124)
- Topics
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular Mechanics and Interactions
- Keywords
- losartan, collagen I synthesis, desmoplasia, tumor stroma, nanotherapeutics, drug penetration, oncolytic herpes simplex virus, pegylated liposomal doxorubicin, cancer-associated fibroblasts, breast cancer, pancreatic cancer, skin cancer, antifibrotic agents, tumor microenvironment
- MeSH terms
- Analysis of Variance, Animals, Breast Neoplasms, Carcinoma, Collagen, Dose-Response Relationship, Drug, Doxorubicin, Female, Humans, Immunohistochemistry, Pancreatic Neoplasms, Polyethylene Glycols, Skin Neoplasms, Polymerase Chain Reaction, Drug Delivery Systems, Mice, SCID, DNA Primers, Simplexvirus, Losartan, Nanotechnology, Fluorescence Recovery After Photobleaching, Oncolytic Virotherapy, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review